Clinical trial
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activities of CS5007, a Novel EGFR and HER3 Bispecific Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors
NCT07622524 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activities of CS5007, a Novel EGFR and HER3 Bispecific Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors
- Lead sponsor
- CStone Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 16, 2026
- Completion date
- January 31, 2029
- Enrollment
- 310 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors